Navigation Links
Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
Date:10/28/2010

ent in school-age children.  Worldwide prevalence of ADHD is estimated at 5.3 percent (with large variability), according to a review of this topic published in 2007.

There is no single test to determine if someone has ADHD; instead, a comprehensive evaluation is required.  This evaluation may include a physical examination, psychological testing, review of school and medical records, as well as parent- and teacher-related behavior scales and family interviews.

Although there is no cure for ADHD, there are accepted treatments that help reduce symptoms.  Treatments include educational approaches, behavioral modification, and/or stimulant or nonstimulant medication.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. 52-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus
2. Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreichs Ataxia
3. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
4. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
5. Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
8. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
9. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
10. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
11. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... and Chinese Stem Cell Industry Report, 2014-2017" report ... undifferentiated biological cells that can differentiate into specialized cells ... cells. Stem cell therapy can be applied to treatment ... disease), nervous system diseases, damage or lesion of liver, ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - ... offering. The global companion diagnostics market ... from 2014 to 2019. Factors such as rising need ... companion diagnostics by the pharmaceutical industry, support from regulatory ...
(Date:9/18/2014)... SAN DIEGO , Sept. 18, 2014  MEI Pharma, ... on the clinical development of novel therapies for cancer, announced ... Chief Executive Officer, will present at BioCentury,s NewsMakers in ... at 8:30 a.m. Eastern time from the Millennium Broadway Hotel ... A live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... 18 septembre 2014 Mapi, société créée ... 1974, a été depuis 40 ans l,un ... cliniques traditionnelles par des évaluations recentrées sur ... les impacts économiques des traitements. ... A cours d,une récente conférence téléphonique ...
Breaking Biology Technology:Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 31974 - 2014 - Mapi fête ses 40 ans 2
... , , , ... ) an implantable biological medical device and cardiovascular tissue processing company, ... human cardiac patch since FDA clearance. The surgeries were performed ... Hospital in Ann Arbor, MI by Richard G. Ohye, M.D., associate ...
... ... its B2B sales into the Cloud with the help of EDL,s CloudCraze eCommerce application. ... Chicago, Ill. & Lincoln, Neb. ... today announced that LI-COR is moving its B2B sales into the Cloud with the help ...
... , , , ... Life Science Summit (SALSS) today announced that U.S. Representative Diana DeGette ... summit, which opens in Stockholm on August 20, 2009. Ms. ... 2007 and an advisor to President Obama on healthcare reform, will ...
Cached Biology Technology:CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 2CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 3CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 4Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud" 2Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud" 3Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs 2Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs 3Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs 4
(Date:9/18/2014)... Sept. 18, 2014 -- Arizona turned its newborn screening program ... few short months, earning it the first-ever Newborn Screening Quality ... of Dimes presented Will Humble, M.P.H., Arizona,s Department of Health ... today. Mr. Humble established a policy of full transparency for ... newborn blood samples to the lab for analysis, and set ...
(Date:9/18/2014)... rabbitfish which have devastated algal forests in the eastern ... Mediterranean basin if their distribution continues to expand as ... by an international team of researchers led by Dr ... of the Mediterranean Institute for Advanced Studies in Spain, ... Members of the team surveyed more than 1000 kilometres ...
(Date:9/18/2014)... of the fish world, are the ideal animal in ... They,ve moved from the ocean into tens of thousands ... time changing their skeleton to adapt to the new ... of sticklebacks now have turned up one of the ... simple change in that gene,s regulation in a freshwater ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Tropical fish a threat to Mediterranean Sea ecosystems 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3
... that living a stressful lifestyle can take its toll, making us ... around the office. The same appears to be true of ... published Nov. 10 in the journal Nature , dopamine-releasing neurons ... a lifestyle that requires lots of energy, creating stress that could ...
... a foreign object such as a catheter enters the body, ... a slick coating a biofilm that is highly ... be defeated by a basic approach of conventional means. Instead ... the key players in the network and how they operate. ...
... , The researchers characterize their new technique as a neat ... microscopy, but it,s more like the difference between finding the ... until you fall over it, or using a flashlight. In ... the National Institute of Standards and Technology (NIST) and the ...
Cached Biology News:Stress takes its toll in Parkinson's disease 2Research provides new leads in the case against drug-resistant biofilms 2AFM positioning: Shining light on a needle in a haystack 2
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human Legumain Affinity Purified Polyclonal Ab...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: